Atg7

Alborixin is a potent inhibitor of the PI3K-AKT signaling pathway that promotes autophagy. It facilitates the clearance of intracellular and extracellular amyloid-β by upregulating key autophagy-related proteins such as BECN1, ATG5, and ATG7, while enhancing lysosomal activity. This mechanism yields a reduction in amyloid-β-mediated neurotoxicity, positioning Alborixin as a valuable tool for research related to Alzheimer's disease and other neurodegenerative conditions.

Bufothionine is a natural alkaloid with anticancer properties, isolated from Cinobufacini. It induces apoptosis through a mitochondria-mediated pathway and effectively reduces serum IL-6 levels while suppressing the expression of p-Stat3tyr705, p-Stat3ser727, and Jak2. Bufothionine also promotes autophagy by upregulating key autophagy-related proteins Atg5, Atg7, and LC3Ⅱ, while inhibiting PIM3 expression. Its efficacy in preclinical models demonstrates significant anti-cancer activity against gastric cancer and highlights its potential role in therapeutic applications.

Antitumor agent-82 is a potent antitumor compound that primarily exerts its effects through the induction of autophagy via the ATG5/ATG7 signaling pathway. This compound demonstrates significant anti-proliferative activity against various cancer cell lines, making it a valuable tool for cancer research. Antitumor agent-82 can be utilized in studies aimed at understanding autophagy's role in tumor progression and therapeutic resistance.

Antitumor agent-199 is an antitumor compound that demonstrates significant antiproliferative effects across various tumor cell lines. It effectively induces autophagy in cancer cells by activating the ATG5/ATG7 pathway. This agent is valuable for research applications focused on cancer biology and therapeutic development.

ATG7-IN-2 is a potent inhibitor of ATG7, demonstrating an IC50 of 0.089 μM. This compound effectively inhibits the autophagy marker LC3B, making it a valuable tool for studies involving autophagy modulation. Researchers can utilize ATG7-IN-2 to investigate the role of autophagy in various biological processes and disease states.

ATG7-IN-1 is a selective inhibitor of the autophagy-related protein ATG7, exhibiting an IC50 of 62 nM. This compound interferes with autophagy processes by disrupting the function of ATG7, making it a valuable tool for research in autophagy regulation. It is particularly useful for studies investigating the role of autophagy in various diseases, including cancer and neurodegenerative disorders.

ATG7-IN-3 is a highly effective inhibitor of ATG7, exhibiting an IC50 of 0.048 μM. This compound disrupts autophagy by preventing the formation of LC3B puncta, a critical process in the autophagic pathway. Research applications include investigations into glioma and colon cancer, making it a valuable tool for studying the role of autophagy in cancer biology.